美国临床肿瘤协会/美国病理医师学院乳腺癌HER2检测指南的解读及展望

被引：10

作者：

龚芸 ^{[1
]}

肖春花 ^{[2
]}

付丽 ^{[3
]}

机构：

[1] Department of Pathology, the University of Texas M D Anderson Cancer Center

[2] 天津医科大学附属肿瘤医院乳腺外一科

[3] 乳腺病理研究室教育部乳腺癌防治研究重点实验室教育部长江学者奖励计划乳腺癌创新团队

来源：

中华病理学杂志 | 2009年 / 12期

关键词：

D O I：

暂无

中图分类号：

R686 [筋腱、韧带、滑囊疾病及损伤];

学科分类号：

1002 ; 100210 ;

摘要：

<正> HER2癌基因位于17号染色体长臂,编码与人表皮生长因子受体高度同源的跨膜酪氨酸激酶受体。HER2状态对乳腺癌患者治疗方案的选择和预后预测非常重要。HER2阳性(即HER2蛋白过度表达或HER2基因扩增)可见于15%～20%乳腺癌,并与临床预后差、对激素治疗及某些化疗反应不佳相关。更重要的是,HER2状态是预测肿瘤对HER2靶向治疗有无反应的关键指标。其阳性状态是使用抗HER2靶向治疗药物曲妥珠单抗(即赫赛汀)的必备条件,近来也被用来判断患者能否进行拉普替尼(一种小分子

引用

共 7 条

[1]

美国临床肿瘤学会/美国病理学医师学院乳腺癌HER2检测指南简介[J]. 步宏,郑杰.中华病理学杂志. 2007(07)

[2]

Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study[J] . Yun Gong,Kai Yan,Feng Lin,Keith Anderson,Christos Sotiriou,Fabrice Andre,Frankie A Holmes,Vicente Valero,Daniel Booser,John E Pippen,Svetislava Vukelja,Henry Gomez,Jaime Mejia,Luis J Barajas,Kenneth R Hess,Nour Sneige,Gabriel N Hortobagyi,Lajos Pusztai,W Fraser Symmans.Lancet Oncology . 2007 (3)

[3] Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists [J].

Dietel, M. ;

Ellis, I. O. ;

Hoefler, H. ;

Kreipe, H. ;

Moch, H. ;

Dankof, A. ;

Koelble, K. ;

Kristiansen, G. .

VIRCHOWS ARCHIV, 2007, 451 (01) :19-25

[4] Concordance between central and local laboratory HER2 testing from a community-based clinical study [J].

Reddy, Josina C. ;

Reimann, James D. ;

Anderson, Steven M. ;

Klein, Pamela M. .

CLINICAL BREAST CANCER, 2006, 7 (02) :153-157

[5] Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab [J].

Dybdal, N ;

Leiberman, G ;

Anderson, S ;

McCune, B ;

Bajamonde, A ;

Cohen, RL ;

Mass, RD ;

Sanders, C ;

Press, MF .

BREAST CANCER RESEARCH AND TREATMENT, 2005, 93 (01) :3-11

[6] Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma [J].

Gong, Y ;

Booser, DJ ;

Sneige, N .

CANCER, 2005, 103 (09) :1763-1769

[7]

HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: Comparison of results and correlation with survival[J] . Sanjay Kakar,Nick Puangsuvan,Jane M. Stevens,Romualda Serenas,George Mangan,Shalini Sahai,Michael L. Mihalov.Molecular Diagnosis . 2000 (3)

← 1 →